Malignant tumor of fallopian tubes

Malignant tumor of the fallopian tubes, also known as primary fallopian tube carcinoma (PFTC), is a rare gynecological cancer that originates in the fallopian tubes — the structures that connect the ovaries to the uterus. It is one of the rarest cancers of the female reproductive tract. In recent years, growing evidence suggests that many cancers previously classified as ovarian or peritoneal high-grade serous carcinomas may actually originate in the fallopian tube epithelium, particularly from the fimbriated (distal) end. This has significantly changed the understanding of the disease and its relationship to ovarian cancer. The most common histological subtype is serous adenocarcinoma, which closely resembles high-grade serous ovarian cancer. Key symptoms include abnormal vaginal bleeding or watery vaginal discharge, pelvic or abdominal pain, and a pelvic mass. A classic but uncommon triad known as 'hydrops tubae profluens' — consisting of intermittent colicky pelvic pain, watery vaginal discharge, and a pelvic mass that decreases in size after the discharge — is considered characteristic but is rarely observed. Many patients present at advanced stages because early symptoms are nonspecific and may be attributed to other conditions. Treatment follows protocols similar to those used for epithelial ovarian cancer and typically involves cytoreductive surgery (including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymph node sampling) followed by platinum- and taxane-based chemotherapy. Targeted therapies, including PARP inhibitors and anti-angiogenic agents such as bevacizumab, may be used in appropriate cases, particularly in patients with BRCA1 or BRCA2 mutations. Genetic predisposition plays an important role, as women carrying germline BRCA1 or BRCA2 mutations have a significantly increased risk of developing fallopian tube carcinoma. Prognosis depends on the stage at diagnosis, with early-stage disease having a more favorable outcome.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Malignant tumor of fallopian tubes